Vireo Growth Q3 Revenue Jumps 177% to $253.7M on M&A

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) reported third-quarter 2026 GAAP revenue of $253.7 million on 10 November 2026, up 176.7% from $91.7 million a year earlier, the Minneapolis-based cannabis and agricultural markets operator said. GAAP gross profit rose 188.2% to $107.8 million, lifting gross margin 170 basis points to 42.5%. Adjusted EBITDA climbed 68.1% to $42.7 million, but the Adjusted EBITDA margin fell 1,090 basis points to 16.8% as lower-margin non-cannabis sales scaled to $55.6 million from zero. Cash stood at $106.8 million.

Context — Why Vireo's Q3 Growth Matters for Cannabis Consolidation

Vireo's quarter is the clearest read yet on how roll-up strategies are reshaping US cannabis. The company closed the PharmaCann Colorado retail assets and the C21 Investments deal in Nevada, adding three Silver State dispensaries and roughly 104,000 square feet of cultivation and production capacity. It also acquired a 49% interest in a joint venture holding PhytoNatural, which carries a Pennsylvania clinical registrant license.

Management framed the quarter as proof the integration model is working. CEO John Mazarakis said the company sees "encouraging results," pointing to 4% pro forma year-over-year retail revenue growth as a proxy for same-store sales. He tied that to local teams integrating acquisitions and strengthening brands across markets.

Vireo's own prior quarter gives the immediate comparison. Sequential revenue rose 21.2% from $209.3 million in Q2 2026, while Adjusted EBITDA grew just 2.9% from $41.5 million. The gap between top-line and EBITDA growth is the story: the company is buying revenue faster than it is buying profit.

The catalyst chain runs through a pipeline of announced but unclosed deals. Vireo announced an agreement to acquire select Cannabist Company assets across Colorado, Illinois, Massachusetts, and New Jersey, plus four definitive agreements expected to build a vertically integrated Ohio platform with eight dispensaries. An all-stock merger with Planet 13 Holdings would expand Nevada and Florida and add Illinois.

Macro conditions for small-cap cannabis remain restrictive, and the company did not disclose its cost of capital beyond the facilities it named. Vireo's answer has been to diversify into agricultural supply, where it secured an $85.0 million five-year asset-based revolver with Bank of Montreal.

Data — What Vireo's Numbers Show

The split between cannabis and non-cannabis is where margins compress. GAAP cannabis revenue rose 116.0% to $198.1 million, while non-cannabis revenue went from nothing to $55.6 million. Adjusted cannabis gross margin slipped 450 basis points to 50.9%, and adjusted non-cannabis gross margin came in at 15.0%.

Metric	Q3 2026	Q3 2025	Change
GAAP revenue	$253.7M	$91.7M	+176.7%
GAAP gross profit	$107.8M	$37.4M	+188.2%
Adjusted EBITDA	$42.7M	$25.4M	+68.1%
Adjusted EBITDA margin	16.8%	27.7%	-1,090 bps

Sequentially, the same pattern holds. Adjusted cannabis EBITDA margin fell 190 basis points to 20.5% from 22.4%, and adjusted non-cannabis EBITDA margin dropped 240 basis points to 3.9% from 6.3%. Total Adjusted EBITDA margin narrowed 300 basis points from 19.8%.

Balance-sheet use is material. Long-term debt was $293 million, and net debt, defined as long-term debt excluding convertible debt less cash, was $186.2 million. Total current assets excluding income taxes receivable were $349.0 million against $153.2 million in current liabilities on the same basis. Pro forma revenue, which treats the C21, PharmaCann Colorado, and Cannabist Colorado deals as if closed on 1 July 2026, was $277.0 million.

Vireo reported 56.9 million Treasury Method Shares Outstanding at a $10.00 reference price, comprising 51.8 million subordinate voting shares on an as-converted basis plus RSUs, convertible debt shares, escrow shares, earn-out shares, and in-the-money warrants and options.

Analysis — What Vireo's Margin Compression Means for Cannabis Tickers

The second-order effect lands on cannabis peers pursuing the same playbook. When a consolidator reports revenue growth of 177% alongside a 1,090-basis-point margin decline, the market re-rates the whole cohort on integration risk rather than on acquired scale. Tickers exposed to that read-through include Planet 13, whose all-stock merger with Vireo is pending a stockholder vote.

Non-cannabis adjacency cuts both ways. The Bank of Montreal revolver gives Vireo cheaper, bank-grade funding than cannabis-only lenders typically offer, and the $60.0 million real estate term loan at a fixed 8.50% refinanced a $49.0 million seller note that carried 15% interest. That refinancing is a concrete cost-of-capital improvement.

But the non-cannabis segment dilutes group margin. Its 15.0% adjusted gross margin and 3.9% adjusted EBITDA margin are far below the cannabis segment's 50.9% and 20.5%. As non-cannabis scales, group margin falls even when each segment performs as expected.

The counter-argument is that scale precedes efficiency. Mazarakis said the decentralized operating model and a growing leadership bench position the company to build "a platform that is more valuable than the sum of its parts." If integration costs are one-time, the current margin trough may not be structural.

A real limitation: the company has not provided a reconciliation of its Adjusted EBITDA outlook to net income, citing unpredictable items including income tax expense, purchase accounting, contingent consideration fair-value changes, and transaction costs. Investors cannot see the GAAP earnings path from the guidance alone.

Positioning follows the deal calendar. Event-driven holders are anchored to the Planet 13 vote on 10 December 2026, while fundamental holders weigh a company whose annualized GAAP revenue run rate now exceeds $1 billion against $186.2 million in net debt.

Outlook — What to Watch Next for Vireo Growth

Vireo guided Q4 2026 revenue to $250 million to $265 million with Adjusted EBITDA of $45 million to $48 million. That range includes FLUENT results only from 9 November 2026, the closing date, and reflects an expected sequential decline and seasonality in the non-cannabis business. It excludes pending acquisitions, which the company estimated could have added $45 million to $55 million of revenue and $5 million to $6 million of Adjusted EBITDA had they closed before the quarter began.

For Q1 2027, guidance is $280 million to $300 million of revenue and $53 million to $56 million of Adjusted EBITDA, including a full quarter of FLUENT and again excluding pending deals. Those unclosed acquisitions could add $50 million to $60 million of revenue and $7 million to $8 million of Adjusted EBITDA.

The clearest near-term catalyst is Planet 13's special stockholder meeting on 10 December 2026, where holders vote on the merger. Closing the Ohio agreements and the Cannabist asset purchase would move the company toward its stated expectation of roughly 270 dispensaries across 15 states, up from about 210 operational dispensaries in 10 states today.

The company said it intends to guide on a sequential, quarterly basis and does not plan full-year guidance while it keeps acquiring. It repurchased 216,200 subordinate voting shares for $2.5 million under its August NCIB.

Frequently Asked Questions

What does Vireo's Q3 2026 revenue growth mean for retail investors?

It shows how much of Vireo's growth comes from acquisitions rather than existing stores. The 4% pro forma retail revenue growth management cited as a same-store proxy is the organic signal; the 176.7% headline figure is mostly closed deals. Investors should track pro forma growth and segment margins, not just the top line.

Why did Vireo's Adjusted EBITDA margin fall 1,090 basis points?

The margin fell because non-cannabis revenue, which earns roughly 15.0% adjusted gross margin, grew from zero to $55.6 million and diluted the group mix. Cannabis margins also narrowed 450 basis points to 50.9%. Group Adjusted EBITDA still rose 68.1% in dollars even as the percentage margin compressed.